DEODORANT FORMULATIONS

Abstract: A deodorant formulation comprises a lower alcohol, from 0.2 to 2% w/w of an amino-lower or-middle alkanol and from 0 to 60% w/w of water. A particularly suitable amino alkanol is 2-amino-2-methylpropan-1-ol. The formulation may be presented in any conventional form, such as a roll-on, spray, aerosol or stick formulation, or it may be presented as impregnated moist tissues.

Description: DEODORANT FORMULATIONS The present invention relates to quick-drying deodorant formulations. In order to produce quick-drying formulations it is customary to use an aqueous ethanol base due to its high volatility. However typical alkaline deodorant agents such as sodium bicarbonate are not soluble in ethanol and must therefore be produced as opaque gels or suspensions. Active ingredients which are soluble in ethanol, such as antibacterials, can only prevent the formation of malodour and sorbants such as zinc ricinoleate, whilst reducing existing malodour also tend to absorb the perfume which is usually included in deodorant formulations. It has now surprisingly been discovered that certain amino alcohols can be employed as deodorant agents and, because they are soluble in aqueous alcohol bases, it is possible to produce clear formulations and so to avoid the difficulties of providing stable suspensions. Such amino alcohols not only suppress the formation of axillary malodour but can also combat existing malodour. Accordingly the present invention provides a deodorant formulation comprising a lower alcohol, from 0.2 to 2% w/w of an amino-lower or-middle alkanol and from 0 to 60% w/w of water. Suitable amino-lower or-middle alkanols have up to 10 carbon atoms in a straight or branched chain bearing from one to three hydroxy groups and at least one amino group on a carbon atom not bearing a hydroxy group. The amino group may be substituted with one alkyl group, usually a C16 alkyl group. A particularly suitable amino alkanol is 2-amino-2- methylpropan-l-ol. Preferably the formulation contains from 0.5 to 1% w/w of the amino alkanol. The exact proportion of lower alcohol in the formulation will depend on the type of presentation. The alcohol content will not usually exceed 70% by weight, the lower limit will generally be about 15%. Preferably the lower alcohol has up to six carbon atoms, most preferably it is ethanol. Preferably the formulation contains from 20 to 408 w/w of water. The formulation may be presented in any conventional form, such as a roll-on, spray, aerosol, or stick formulation, or it may be presented as impregnated moist tissues. Conventional accessory ingredients, such as thickeners, perfumes and preservatives may be included as appropriate to the presentation. Thus a roll-on formulation may include a thickener such as hydroxypropyl cellulose whereas an aerosol formulation would not require any thickener. For aerosol formulations suitable propellants would be dichlorodifluoromethane, or a mixture of fluorocarbons and/or hydrocarbons, such n-butane, isobutane and n-propane. For stick formulations, the formulation typically also includes a soap, such as sodium stearate. The molten product is run into a mould to form a stick. When presented as moist tissues, about 5cm3 of the formulation is applied to each crepe tissue about 20cm2 in area. The tissues are then individually packaged in sealed sachets. Suitable accessory ingredients for a formulation to be applied to such tissues include emollients, perfumes and preservatives. Other conventional ingredients may also be included such as compatible antiperspirants and/or antimicrobial agents. One suitable antimicrobial agent is Chlorhexidine El, 6-di- (N-chlorophenyldiquanido)-hexane] which may be included in the formulation at from 0.2 to 4%, preferably about 1% w/w. A preferred antimicrobial agent however is Irgasan DP 300 (Triclosan or 2, 4, 4 -trichloro - 2-hydroxydiphenylether) included at from 0.1 to 1% w/w. Formulations according to the invention may be produced by conventional methods. Typically the amino alkanol is dissolved in the alcohol and then water is added as required. The formulations are then filled into conventional dispensers, such as roll-on dispensers, spray-pump packs or aerosol dispensers, holders for a self-supporting stick compositions, or impregnated into tissues. Rne invention will now be illustrated with reference to the following Examples: Example 1 Aqueous alcoholic roll-on % w/w De-ionized water 37.8% Hydroxypropyl cellulose 0.7% Amino-methyl-propanol 1.0% Alcohol 60.0% Perfume 0.5% Procedure The hydroxypropyl cellulose is dissolved in part of the alcohol with a high shear stirrer and allowed to solvate. The amino methyl propanol and perfume are dissolved in the remaining alcohol and the mixture is added to the batch. Water and the other ingredients are added slowly with stirring. Example 2 Aerosol Deodorants % w/w Amino-methyl-propanol 18 Irgasan DP 300 0.18 Perfume 0.5% Alcohol 50% Propellant 12 48.4% (Propellant 12 is dichlorodifluoromethane). The composition is produced conventionally and filled into aerosol spray cans. Clinical Trial Deodorant A B (test product) (control product) Amino-methyl -propanol 1.008 Alcohol ' 60.00% 60.008 Water 39.00% 40.00% 14 male volunteers first used soap free of antimicrobials in their axillae, for a period of 8 days; no deodorants or antiperspirants were applied. On day 8 each volunteer had the malodour in their axillas assessed by 4 trained observers. One half of the group had deodorant A applied to their right axilla and deodorant B applied to their left axilla whilst the other half had A applied on the left and B applied on the right. Axillary malodour was then reassessed by the observers after the products had dried, then 3h, 5 and 24 hours later. The scores recorded by each observer for each subject were combined to give 5 mean scores for deodorants A and B. Mean ytercentage changes in odour score were calculated by comparing the mean scores for the active treated (deodorant A) and the control treated (deodorant B) axilla with the control ratio before treatment: % change in malodour, x hours after treatment = EMI6.1 A = mean score for axilla treated with deodorant A, x hours after treatment. B = mean score for axilla treated with deodorant B, x hours after treatment. C = control ratio = mean score for axilla before treatment with deodorant A mean score for axilla before treatment with deodorant B Immediately after application deodorant A reduced the mean malodour score by 62% compared with deodorant B (p < 0.01). After 3 and 5 hours, 27% and 33% reductions in axillary malodour were obtained with deodorant A compared to deodorant B.

Claims: CLAIMS 1. A deodorant formulation comprising a lower alcohol, from 0.2 to 28 w/w of an amino-lower or-middle alkanol and from 0 to 60% of water. 2. A deodorant formulation according to claim 1 wherein the amino-lower or-middle alkanol has up to 10 carbon atoms in a straight or branched chain bearing from one to three hydroxy groups and at least one amino group on a carbon atom not bearing a hydroxy group, and wherein the amino group is optionally substituted with one C16 alkyl group. 3. A deodorant formulation according to claim 2 wherein the amino alkanol is 2-amino 2-methylpropan-l -ol. 4. A deodorant formulation according to any one of claims 1 to 3 wherein the formulation contains from 15 to 708 w/w of lower alcohol. 5. A deodorant formulation according to any one of claims 1 to 4 wherein the alcohol is ethanol. 6. A deodorant formulation according to any one of claims 1 to 5 wherein the formulation comprises from 20 to 40% w/w of water. 7. A deodorant formulation according to any one of claims 1 to 6 also comprising an antimicrobial agent. 8. A deodorant formulation according to claim 7 wherein the antimicrobial agent is 0.1 to 18 w/w of 2, 4, 4 - trichloro - 2-hydroxydiphenylether. 9. A method of deodorising the human body comprising the application of a deodorant formulation according to any one of claims 1 to 8.

Inventors: GRAHAM, JUNE
Applicants: BEECHAM GROUP PLC
Application year: 1984
Main classification: A61K7
IPC codes: A61K8, A61L9, A61Q15, A61Q17